April 16, 2025

Is Primary Care Becoming Pay-to-Play?

“It’s a way to practice self-preservation in this field that is punishing patients and doctors alike” — one internist explains why some rural physicians are opting for concierge care despite the access trade-offs.

KFF Health News

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 14, 2025

FDA-Approved COVID-19 Drugs: Safety Risks Assessed

Researchers found most FDA-authorized COVID-19 treatments were not linked to serious adverse events, though risks may rise with tocilizumab or convalescent plasma in specific patients.

Conexiant

April 14, 2025

Inebilizumab Effective for Myasthenia Gravis

CD19+ B-cell-depleting therapy shows significant improvement in function and disease severity in phase III trial of autoimmune neuromuscular disorder.

Conexiant

April 14, 2025

FDA Approves Bevacizumab Biosimilar

Bevacizumab-nwgd is indicated for use in the treatment of certain kinds of colorectal, lung, brain, kidney, and cervical cancers.

The ASCO Post

April 11, 2025

New Self-Injection Option for gMG, CIDP

A prefilled syringe version of VYVGART Hytrulo, which enables adult patients with generalized myasthenia gravis or chronic inflammatory demyelinating polyneuropathy to self-administer treatment in as little as 20 to 30 seconds, has been approved by the FDA.

Conexiant

April 11, 2025

Early Antibiotics Linked to Asthma, Eczema

Researchers found early-life antibiotic use was linked to increased risk of asthma and eczema, but not most other immune diseases, after adjusting for familial factors.

Conexiant

April 10, 2025

FDA to Pilot Animal-Free Models

"This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use."

Reuters

April 09, 2025

Dual Immunotherapy Approved for Advanced CRC

The FDA approved nivolumab with ipilimumab for unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer.

Conexiant